There are lot of Doctors in ASX listed companies, some are...

  1. 1,383 Posts.
    lightbulb Created with Sketch. 445
    There are lot of Doctors in ASX listed companies, some are excellent, some are good and some are exceptionally disgrace in managing a Pharma. I will leave for readers to decide where IMU management sits - a company that has
    • never produced a drug/treatment in last six years and projection is there will nothing for next 2 years
    • have burn >$400M of cash in less than 100 patients,
    • cost time overruns are exceptionally unacceptable;
    • exceptionally high salaries, over crowded management without accountability/responsibility that has completely wiped out shareholders confidence
    • still allocate performance shares in millions without paying a cents for doing nothing;
    • Do not care attitude on share on issue.

    My opinion is that IMU is lifestyle company where management enjoy benefit at the expense of shareholders and most importantly retail holders suffer the most. LC claim to "Believe in Science" is fading and is possibly looking for another round of CR $30-40M, possibly at 1.5C (with again middle finger to retail holders) to support her lifestyle as outside of IMU her professional career is at dead end.

    Personally for me if I get my 60-70% principle back, I will out of this crap by this June. Some investments are worth not discussing and IMU is one of them
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.3¢
Change
0.000(0.00%)
Mkt cap ! $97.07M
Open High Low Value Volume
1.4¢ 1.4¢ 1.2¢ $304.8K 23.56M

Buyers (Bids)

No. Vol. Price($)
57 13718532 1.2¢
 

Sellers (Offers)

Price($) Vol. No.
1.3¢ 5374446 13
View Market Depth
Last trade - 16.10pm 19/06/2025 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.